We are live on ! Find out more
TPST icon

Tempest Therapeutics

23 hedge funds and large institutions have $4.42M invested in Tempest Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.18% less ownership

Funds ownership: 1.2%1.01% (-0.18%)

5% less call options, than puts

Call options by funds: $56K | Put options by funds: $59K

22% less capital invested

Capital invested by funds: $5.66M → $4.42M (-$1.24M)

30% less funds holding

Funds holding: 3323 (-10)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
23
Holders Change
-10
Holders Change %
-30.3%
% of All Funds
0.31%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
1
Increased
9
Reduced
1
Closed
11
Calls
$56K
Puts
$59K
Net Calls
-$3K
Net Calls Change
+$83K
Name Holding Trade Value Shares
Change
Change in
Stake
XT
26
XTX Topco
Cayman Islands
-$134K -12,370 Closed
Fidelity International
27
Fidelity International
Bermuda
-$108K -9,968 Closed
IC
28
Ikarian Capital
Texas
-$87.9K -8,099 Closed
VF
29
Virtu Financial
New York
-$36K -3,316 Closed
BFM
30
Boothbay Fund Management
New York
-$20.2K -1,866 Closed
EGM
31
Engineers Gate Manager
New York
-$19.6K -1,807 Closed
TRCT
32
Tower Research Capital (TRC)
New York
-$9.12K -840 Closed
Citigroup
33
Citigroup
New York
-$811 -75 Closed
RS
34
R Squared
Hong Kong
-$159 -15 Closed

TPST Hedge Fund Activity: Q1 2025 in Review

23 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2025, worth a combined $4.42M — down 22% from $5.66M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TPST and 1 opened new positions — a net loss of 10 holders — while 1 trimmed existing stakes and 9 added.

The largest buyer was UBS Group, adding an estimated $112K. The largest seller was Jane Street, exiting entirely with an estimated $411K sold.

  • 23 institutional investors held Tempest Therapeutics (TPST) as of Q1 2025, down from 33 in Q4 2024.
  • Funds reported $4.42M of Tempest Therapeutics stock for Q1 2025, down 22% quarter-over-quarter.
  • 1 fund opened new Tempest Therapeutics positions in Q1 2025 and 11 closed out, a net change of -10 holders.
  • The largest Tempest Therapeutics buyer in Q1 2025 was UBS Group, an estimated $112K added.
  • The largest Tempest Therapeutics seller in Q1 2025 was Jane Street, an estimated $411K sold.

Based on aggregated 13F filings for Q1 2025.